{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:17:37Z","timestamp":1788419857334,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T00:00:00Z","timestamp":1533600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000948","name":"Pfizer Australia","doi-asserted-by":"publisher","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}],"id":[{"id":"10.13039\/501100000948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie Pty Ltd","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}]},{"name":"Sanofi Australia","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}]},{"name":"Celgene Australian & NZ","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}]},{"name":"Bristol-Myers Squibb Australia Pty Ltd","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Enabling Grant [384330]"],"award-info":[{"award-number":["Enabling Grant [384330]"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Postgraduate Scholarship"],"award-info":[{"award-number":["Postgraduate Scholarship"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Senior Principal Research Fellowship"],"award-info":[{"award-number":["Senior Principal Research Fellowship"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amgen Australia Pty Ltd","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}]},{"name":"Aventis","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}],"id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cabrini Health","award":["unrestricted educational grant"],"award-info":[{"award-number":["unrestricted educational grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1669-x","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T08:28:07Z","timestamp":1533630487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Joshua L.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-1274","authenticated-orcid":false,"given":"Premarani","family":"Sinnathurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Lassere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,7]]},"reference":[{"key":"1669_CR1","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner \u017d, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635\u2013701.","journal-title":"Eur Heart J"},{"key":"1669_CR2","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1136\/ard.2005.050377","volume":"65","author":"DH Solomon","year":"2006","unstructured":"Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006;65:1608\u201312.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.1780370408","volume":"37","author":"F Wolfe","year":"1994","unstructured":"Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481\u201394.","journal-title":"Arthritis Rheum"},{"key":"1669_CR4","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167\u201372.","journal-title":"J Rheumatol"},{"key":"1669_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.autrev.2003.09.004","volume":"3","author":"G Ferraccioli","year":"2004","unstructured":"Ferraccioli G, Gremese E. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers. Autoimmun Rev. 2004;3:261\u20136.","journal-title":"Autoimmun Rev"},{"key":"1669_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.semarthrit.2014.06.006","volume":"44","author":"J Beinsberger","year":"2014","unstructured":"Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum. 2014;44:345\u201352.","journal-title":"Semin Arthritis Rheum"},{"key":"1669_CR7","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2016-209562","volume":"76","author":"D Lacaille","year":"2017","unstructured":"Lacaille D, Avina-Zubieta JA, Sayre EC, Abrahamowicz M. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population\u2014closing the mortality gap. Ann Rheum Dis. 2017;76:1057.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.trsl.2015.05.006","volume":"167","author":"J Shen","year":"2016","unstructured":"Shen J, Shang Q, Tam LS. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Transl Res. 2016;167:138\u201351.","journal-title":"Transl Res"},{"key":"1669_CR9","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1517\/14740338.2015.1111870","volume":"14","author":"MN Di Minno","year":"2015","unstructured":"Di Minno MN, Iervolino S, Zincarelli C, Lupoli R, Ambrosino P, Pizzicato P, et al. Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database. Expert Opin Drug Saf. 2015;14:1905\u201313.","journal-title":"Expert Opin Drug Saf"},{"key":"1669_CR10","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","volume":"53","author":"E Choy","year":"2014","unstructured":"Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014;53:2143\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"1669_CR11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2174\/138161212799504786","volume":"18","author":"MJ Peters","year":"2012","unstructured":"Peters MJ, van Sijl AM, Voskuyl AE, Sattar N, Smulders YM, Nurmohamed MT. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des. 2012;18:1502\u201311.","journal-title":"Curr Pharm Des"},{"key":"1669_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/138161282004140213123852","volume":"20","author":"EA Brezinski","year":"2014","unstructured":"Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20:513\u201328.","journal-title":"Curr Pharm Des"},{"key":"1669_CR13","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","volume":"71","author":"CI Daien","year":"2012","unstructured":"Daien CI, Duny Y, Barnetche T, Daures JP, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012;71:862\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/ard.2010.129916","volume":"70","author":"JD Greenberg","year":"2011","unstructured":"Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:576\u201382.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/acr.22166","volume":"66","author":"A Bili","year":"2014","unstructured":"Bili A, Tang X, Pranesh S, Bozaite R, Morris SJ, Antohe JL, et al. Tumor necrosis factor alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:355\u201363.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1669_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3899\/jrheum.131464","volume":"41","author":"RJ Desai","year":"2014","unstructured":"Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley J. Tumor necrosis factor-alpha inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol. 2014;41:2129\u201336.","journal-title":"J Rheumatol"},{"key":"1669_CR17","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1002\/art.22255","volume":"54","author":"DH Solomon","year":"2006","unstructured":"Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3790\u20138.","journal-title":"Arthritis Rheum"},{"key":"1669_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.trsl.2010.09.005","volume":"157","author":"Z Al-Aly","year":"2011","unstructured":"Al-Aly Z, Pan H, Zeringue A, Xian H, McDonald JR, El-Achkar TM, et al. Tumor necrosis factor-alpha blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res. 2011;157:10\u20138.","journal-title":"Transl Res"},{"key":"1669_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.amjmed.2013.02.016","volume":"126","author":"DH Solomon","year":"2013","unstructured":"Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-alpha blockade with nonbiologic DMARDs. Am J Med. 2013;126:730. e9\u2013730.e17","journal-title":"Am J Med"},{"key":"1669_CR20","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905\u201312.","journal-title":"Arthritis Rheum"},{"key":"1669_CR21","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar4584","volume":"16","author":"L Ljung","year":"2014","unstructured":"Ljung L, Askling J, Rantapaa-Dahlqvist S, Jacobsson L, Group AS. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther. 2014;16:R127.","journal-title":"Arthritis Res Ther"},{"key":"1669_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1445-5994.2007.01431.x","volume":"37","author":"R Buchbinder","year":"2007","unstructured":"Buchbinder R, March L, Lassere M, Briggs A, Portek I, Reid C, et al. Effect of treatment with biological agents for arthritis in Australia: the Australian rheumatology association database. Intern Med J. 2007;37:591\u2013600.","journal-title":"Intern Med J"},{"key":"1669_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137\u201345.","journal-title":"Arthritis Rheum"},{"key":"1669_CR24","unstructured":"World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. World Health Organization. 2016. \n                    http:\/\/apps.who.int\/classifications\/icd10\/browse\/2016\/en\n                    \n                  . Accessed 4 Jan 2018."},{"key":"1669_CR25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2014-206824","volume":"75","author":"AM Gulati","year":"2016","unstructured":"Gulati AM, Semb AG, Rollefstad S, Romundstad PR, Kavanaugh A, Gulati S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Tr\u00f8ndelag Health Study. Ann Rheum Dis. 2016;75:819\u201324.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR26","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/acr.20627","volume":"63","author":"JA Husted","year":"2011","unstructured":"Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63:1729\u201335.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1669_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","volume":"49","author":"SL Westlake","year":"2010","unstructured":"Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49:295\u2013307.","journal-title":"Rheumatology (Oxford)"},{"key":"1669_CR28","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"FGR Fowkes","year":"2010","unstructured":"Fowkes FGR, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841\u20138.","journal-title":"JAMA"},{"key":"1669_CR29","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin E, Go A, Arnett D, Blaha M, Cushman M, et al. AHA statistical update heart disease and stroke statistics\u20142015 update. Circulation. 2015;131:e29\u2013e322.","journal-title":"Circulation"},{"key":"1669_CR30","unstructured":"UCLA: Statistical Consulting Group. How can I model repeated events survival analysis in PROC PHREG? \n                    https:\/\/stats.idre.ucla.edu\/sas\/faq\/how-can-i-model-repeated-events-survival-analysis-in-proc-phreg\/\n                    \n                  . Accessed 12 Aug 2016."},{"key":"1669_CR31","unstructured":"Montemezzani S, Muller S, Sbardella C. Recurrent event survival analysis. Swiss Federal Institute of Technology. 2011. \n                    https:\/\/stat.ethz.ch\/education\/semesters\/ss2011\/seminar\/contents\/presentation_10.pdf\n                    \n                  . Accessed 12 Aug 2016."},{"key":"1669_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v061.c01","volume":"61","author":"L Thomas","year":"2014","unstructured":"Thomas L, Reyes EM. Tutorial: survival estimation for Cox regression models with time-varying coefficients using SAS and R. J Stat Softw. 2014;61:1\u201323.","journal-title":"J Stat Softw"},{"key":"1669_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1669_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","volume":"34","author":"MJ Peters","year":"2004","unstructured":"Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34:585\u201392.","journal-title":"Semin Arthritis Rheum"},{"key":"1669_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","volume":"21","author":"L Li","year":"2015","unstructured":"Li L, Hagberg KW, Peng M, Shah K, Paris M, Jick S. Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis. J Clin Rheumatol. 2015;21:405\u201310.","journal-title":"J Clin Rheumatol"},{"key":"1669_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jbspin.2010.05.001","volume":"77","author":"S Mathieu","year":"2010","unstructured":"Mathieu S, Motreff P, Soubrier M. Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine. 2010;77:542\u20135.","journal-title":"Joint Bone Spine"},{"key":"1669_CR37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","volume":"76","author":"ASL Low","year":"2017","unstructured":"Low ASL, Symmons DPM, Lunt M, Mercer LK, Gale CP, Watson KD, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:654\u201360.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR38","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2015-208995","volume":"75","author":"L Ljung","year":"2016","unstructured":"Ljung L, Rantap\u00e4\u00e4-Dahlqvist S, Jacobsson LTH, Askling J. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis. 2016;75:2087\u201394.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR39","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/art.30654","volume":"64","author":"L Ljung","year":"2012","unstructured":"Ljung L, Simard JF, Jacobsson L, Rantapaa-Dahlqvist S, Askling J, Anti-Rheumatic Therapy in Sweden Study Group. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum. 2012;64:42\u201352.","journal-title":"Arthritis Rheum"},{"key":"1669_CR41","unstructured":"Australian Institute of Health and Welfare. Cardiovascular Health Compendium. 2017. \n                    https:\/\/www.aihw.gov.au\/reports\/heart-stroke-vascular-disease\/cardiovascular-health-compendium\/data\n                    \n                  . Accessed 29 Apr 2018."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1669-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1669-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1669-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T02:51:44Z","timestamp":1569379904000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1669-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1669-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,7]]},"assertion":[{"value":"27 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Twenty ethics committees and organisations have granted approval for the ARAD across each state in Australia (New South Wales: Northern Sydney Local Health District, Cancer Council NSW; Victoria: Cabrini Health, Monash University, Royal Children\u2019s Hospital, St Vincent\u2019s Hospital, Cancer Council Victoria; Queensland: Queensland Government; South Australia: The South Australian Department of Health and Ageing, Women\u2019s and Children\u2019s Hospital SA Health Network; Western Australia: Department of Health WA, Fiona Stanley Hospital, Rockingham General Hospital, Royal Perth Hospital, Southern Metropolitan Health Service, Government of WA; Tasmania: Tasmania Health, University of Tasmania; Australian Capital Territory: ACT Health and Community Care). Approval has also been granted by the Australian Institute of Health and Welfare, the Australian Government Department of Health and the Department of Defence and Veterans\u2019 Affairs, the cancer registry in each state (New South Wales, Victoria, Queensland, South Australia, Western Australia, Tasmania, Australian Capital Territory, Northern Territory) and the National Cancer Statistics Clearing House. All participants provide informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"171"}}